You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Multidrug-resistant Cancer Cells Facilitate E1-independent Adenoviral ReplicationImpact for Cancer Gene Therapy
|
|---|---|
| Published in |
Cancer Research, January 2004
|
| DOI | 10.1158/0008-5472.can-0482-2 |
| Pubmed ID | |
| Authors |
Per S. Holm, Hermann Lage, Stephan Bergmann, Karsten Jürchott, Gabriel Glockzin, Alexandra Bernshausen, Klaus Mantwill, Axel Ladhoff, Anke Wichert, Joe S. Mymryk, Thomas Ritter, Manfred Dietel, Bernd Gänsbacher, Hans-Dieter Royer |
| Abstract |
Resistance to chemotherapy is responsible for a failure of current treatment regimens in cancer patients. We have reported previously that the Y-box protein YB-1 regulates expression of the P-glycoprotein gene mdr1, which plays a major role in the development of a multidrug resistant-tumor phenotype. YB-1 predicts drug resistance and patient outcome in breast cancer. Thus, YB-1 is a promising target for new therapeutic approaches to defeat multidrug resistance. In drug-resistant cancer cells and in adenovirus-infected cells YB-1 is found in the nucleus. Nuclear accumulation of YB-1 in adenovirus-infected cells is a function of the E1 region, and we have shown that YB-1 facilitates adenovirus replication. Here we report that E1A-deleted or mutant adenovirus vectors, such as Ad312 and Ad520, replicate efficiently in multidrug-resistant (MDR) cancer cells and induce an adenovirus cytopathic effect resulting in host cell lysis. Thus, replication-defective adenoviruses are a previously unrecognized vector system for a selective elimination of MDR cancer cells. Our work forms the basis for the development of novel oncolytic adenovirus vectors for the treatment of MDR malignant diseases in the clinical setting. |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | 3% |
| Russia | 1 | 3% |
| Unknown | 28 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 27% |
| Student > Bachelor | 5 | 17% |
| Student > Ph. D. Student | 5 | 17% |
| Other | 2 | 7% |
| Professor > Associate Professor | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 5 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 16 | 53% |
| Medicine and Dentistry | 4 | 13% |
| Computer Science | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 6 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2023.
All research outputs
#3,310,984
of 23,006,268 outputs
Outputs from Cancer Research
#2,833
of 17,945 outputs
Outputs of similar age
#9,136
of 134,141 outputs
Outputs of similar age from Cancer Research
#7
of 152 outputs
Altmetric has tracked 23,006,268 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,945 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 134,141 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 152 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.